Tech Company Financing Transactions

Allakos Funding Round

Allakos, operating out of Redwood City, secured $100 million in investment from New Enterprise Associates, 3x5 Special Opportunity Partners and Alta Partners.

Transaction Overview

Company Name
Allakos
Announced On
12/14/2017
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series B
Investors

New Enterprise Associates (Lead Investor) (Paul Walker)

3x5 Special Opportunity Partners

Alta Partners (Robert Alexander)

LifeSci Venture Partners

Partner Fund Management

Redmile Group

RiverVest Venture Partners (John McKearn)

Roche Venture Fund

Rock Springs Capital

Samsara BioCapital

Proceeds Purpose
Proceeds from the financing will be used to advance Allakos's development programs including the Company's lead clinical candidate, AK002, which is being evaluated in patients with eosinophilic gastritis, indolent systemic mastocytosis (ISM), urticaria and severe allergic conjunctivitis.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
975 Island Dr. 201
Redwood City, CA 94065
USA
Phone
(650) 597-5002
Website
www.allakos.com
Email Address
[email protected]
Overview
Allakos (Nasdaq: ALLK) is a biotechnology company developing antibodies targeting receptors that modulate the activity of immune effector cells involved in inflammation and tissue damage.
Profile
Allakos LinkedIn Company Profile
Social Media
Allakos Company Twitter Account
Company News
Allakos News
Facebook
Allakos on Facebook
YouTube
Allakos on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Robert Alexander
  Robert Alexander LinkedIn Profile  Robert Alexander Twitter Account  Robert Alexander News  Robert Alexander on Facebook
Chief Medical Officer
Henrik Rasmussen
  Henrik Rasmussen LinkedIn Profile  Henrik Rasmussen Twitter Account  Henrik Rasmussen News  Henrik Rasmussen on Facebook
Chief Operating Officer
Adam Tomasi
  Adam Tomasi LinkedIn Profile  Adam Tomasi Twitter Account  Adam Tomasi News  Adam Tomasi on Facebook
VP - Bus. Development
Simon Greenwood
  Simon Greenwood LinkedIn Profile  Simon Greenwood Twitter Account  Simon Greenwood News  Simon Greenwood on Facebook
VP - General Counsel
Mark Asbury
  Mark Asbury LinkedIn Profile  Mark Asbury Twitter Account  Mark Asbury News  Mark Asbury on Facebook
VP - Regulatory Affairs
Sally Bolmer
  Sally Bolmer LinkedIn Profile  Sally Bolmer Twitter Account  Sally Bolmer News  Sally Bolmer on Facebook

 

 

Browse more venture capital transactions:

Prev: 12/14/2017: Merchbar venture capital transaction
Next: 12/14/2017: Virtual Incision venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.